Blog

Technical knowledge

Industry Trends

Home

Olympus is conducting a voluntary recall of ViziShot 2 FLEX EBUS - TBNA needles manufactured before May 12, 2025.

Release time:

2025-09-09

Category:

　　Olympus is conducting a voluntary recall of ViziShot 2 FLEX EBUS - TBNA needles manufactured before May 12, 2025, due to the risk that components of the device may detach during surgery, resulting in adverse events including patient injuries and one death.

Previous page

Beijing Friendship Hospital showcases two domestically developed innovative endoscopic devices.

Olympus X1 domestically produced lens body approved for market launch.

Next page

Related News

Future Development Direction

Combining industry technology breakthroughs in 2025 with clinical needs-oriented approaches, medical endoscopes will undergo profound evolution in the fields of intelligence and miniaturization, moving toward greater precision, enhanced flexibility, and adaptability to multiple scenarios. At the same time, this trend will also give rise to innovative forms that integrate with multiple technologies. The following are specific development directions: Intelligent Direction

In addition to the previously effective policies, the new regulations issued by the National Medical Products Administration (NMPA) concerning high-end medical devices provide stronger support for innovation and development in the medical endoscopy industry. The key contents are as follows, according to the NMPA:

The impact of the policy on businesses and users

Enterprises: Policies provide a solid backing for corporate innovation and development. The special review process for innovative medical devices has significantly shortened the approval cycle for high-end endoscopes, enabling companies to bring their R&D achievements to market more quickly—for instance, Weitong’s intelligent-focus endoscope has been swiftly approved and launched. Meanwhile, the establishment of standardized technical organizations and the dynamic adjustment of product categories have set clear boundaries for corporate R&D, reducing its randomness and uncertainty. At the same time, centralized procurement and medical insurance policies are driving enterprises toward transformation. Under the DRG/DIP payment reform, medical institutions are increasingly favoring cost-effective equipment, prompting companies to shift from simply selling devices to adopting an integrated model that includes “equipment + consumables + services.” Moreover, preferential procurement policies aimed at grassroots-level facilities are guiding enterprises to develop simplified endoscopic products tailored specifically for primary care settings. Additionally, enhanced post-market surveillance requirements are compelling companies to increase their investments in quality testing and adverse-event traceability, thereby raising compliance costs.

A “visualization tool” for exploring the human body’s “microscopic world”

As the cornerstone of modern minimally invasive medicine, medical endoscopes have fundamentally transformed traditional diagnostic and therapeutic approaches. Without the need for large incisions, these devices enable doctors to "penetrate" deep into the human body, facilitating precise diagnosis and minimally invasive treatment of diseases. From removing small gastrointestinal polyps to performing complex laparoscopic surgeries, endoscopes play an irreplaceable role in a wide range of procedures. In this article, we’ll thoroughly explore this “tool for exploring the human body”—covering its core principles, mainstream types, application scenarios, and purchasing tips.

The Chinese Medical Association’s 2025 Annual Conference on Digestive Endoscopy (CCDE2025) concluded in Hangzhou.

The Chinese Medical Association’s 2025 Annual Conference on Digestive Endoscopy (CCDE2025) concluded in Hangzhou, where Coman Medical showcased its innovative endoscopic solutions. On the same day, an industry research report indicated that a wave of new endoscopic products from both domestic and international markets will be launched in 2025, and high-end, premium-quality endoscopes will drive a new round of demand for industry upgrades and replacements.

Olympus Announces New Corporate Strategy for 2026

Olympus announced its new corporate strategy for 2026, revealing plans to cut 2,000 jobs worldwide and achieve cost savings of $150 million. The company also plans to invest in AI-powered endoscopic solutions. Furthermore, Olympus made it clear that at the beginning of 2026, it will unveil a brand-new decade-long strategy focusing on areas such as single-use endoscopes and AI-enhanced conventional endoscopy.

Contact Us

Tel: +86-431-87675449

Email: sales@ocean-opto.com

Address: Haoyue Avenue, Lvyuan District, Changchun City, Jilin Province, China

Welcome to inquire about our products.

Click the button to submit your request information, and we’ll contact you as soon as we receive it.

Weihai Optics

Scan the code to add us on WeChat.

Powered by 300.cn Changchun SEO

License